Nora E. Brennan

Nora Brennan has served as the Chief Financial Officer since May 2022. Prior to joining Spectrum, she was the Chief Financial Officer of Fore Biotherapeutics, a private precision oncology company pioneering the development of cancer therapies guided by functional genomics. Prior to Fore, she was the Chief Financial Officer of TELA Bio, Inc., where she guided the company through a successful IPO and follow-on financing. Previously, Ms. Brennan spent 11 years as the Senior Vice President of Treasury and Investor Relations at Integra LifeSciences Holdings Corporation, where she served in numerous capacities and led Integra through a myriad of financings. She was key to the capital markets strategy over a significant period of time and successfully integrated 18 acquisitions leading to significant revenue growth for the company. For the past 15 years she has served on management teams of publicly traded life science companies raising more than $2 billion in capital, building finance organizations and supporting operations from early development stage into commercialization.

She earned her B.A. in Economics from the University of Illinois at Urbana-Champaign and received her MBA from the University of Chicago Booth School of Business.

Ms. Brennan is currently serving as a Director and Audit Chair at Artios Pharma Limited, a privately held biotech company.